Spero Therapeutics Inc (fra:2HA) Share Price

Company Profile

Business description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Contact
675 Massachusetts Avenue
14th Floor
CambridgeMA02139
USA
T: +1 857 242-1600
E: [email protected]
https://www.sperotherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
25

Recommended

Near-term pain, long-term potential.

Dan Baker | 22 October 2026

We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.

Malik Ahmed Khan, CFA | 22 October 2026

Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.

Seth Goldstein, CFA | 22 October 2026

Index	Last price	Change	% Change
All Ordinaries	8,917.10	39.50	-0.44%
CAC 40	7,811.26	110.42	-1.39%
DAX 40	25,371.75	273.29	-1.07%
Dow JONES (US)	52,867.98	11.89	0.02%
FTSE 100	10,725.03	27.85	-0.26%
HKSE	22,934.68	717.19	-3.03%
NASDAQ	26,008.86	694.00	-2.60%
Nikkei 225	62,907.84	1,713.40	-2.65%
NZX 50 Index	13,746.84	14.45	-0.11%
S&P 500	7,663.43	93.74	-1.21%
S&P/ASX 200	8,793.20	38.10	-0.43%
SSE Composite Index	3,658.03	55.00	-1.48%